Table 3. Multivariate Cox proportional hazards analysis of survival factors in the PROS1 comparison group.
| Characteristic | HR | 95% CI | p-value |
|---|---|---|---|
| Age_at_diagnosis | 1 | 1.00, 1.01 | 0.3 |
| Gender | |||
| Female | — | — | |
| Male | 1.09 | 0.94, 1.27 | 0.2 |
| Race_new | |||
| White | — | — | |
| Black or african american | 1.06 | 0.78, 1.45 | 0.7 |
| Other | 0.84 | 0.65, 1.10 | 0.2 |
| Stage | |||
| Stage I | — | — | |
| Stage II | 1.45 | 1.20, 1.77 | <0.001 |
| Stage III | 1.97 | 1.61, 2.40 | <0.001 |
| Stage IV | 1.51 | 1.14, 2.01 | 0.004 |
| Tissue_or_organ_of_origin | |||
| Lower lobe, lung | — | — | |
| Lung, NOS | 1.05 | 0.67, 1.65 | 0.8 |
| Middle lobe, lung | 1.46 | 0.96, 2.20 | 0.076 |
| Pleura, NOS | 1.73 | 1.36, 2.19 | <0.001 |
| Upper lobe, lung | 1.28 | 1.06, 1.54 | 0.009 |
| Treatment_type2 | |||
| Chemotherapy | — | — | |
| Ancillary Treatment | 1.41 | 0.76, 2.62 | 0.3 |
| Immunotherapy (Including Vaccines) | 2.26 | 0.83, 6.16 | 0.11 |
| Pleurodesis, NOS | 1.09 | 0.79, 1.51 | 0.6 |
| Radiation | 1.13 | 0.95, 1.35 | 0.2 |
| Targeted Therapy | 1.1 | 0.91, 1.33 | 0.3 |
| Laterality | |||
| Left | — | — | |
| Right | 1.18 | 1.02, 1.38 | 0.026 |
| Counts_PROS1 | 0.94 | 0.88, 0.99 | 0.025 |
Survival analysis of PROS1 in comparison group (Multivariable).